Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03854019 · ClinicalTrials.gov registry record · Phase 3
Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease
A Phase 3 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
NCT03854019 is a Phase 3 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 20 participants.
The verdict
NCT03854019, a Phase 3 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to assess efficacy and safety of dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg) in patients with irritability due to Huntington's disease.
Interventions
- DRUG Placebo
- DRUG Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-08-05 |
| Est. Completion | 2022-11-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03854019
The ClinicalTrials.gov registry entry for NCT03854019 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03854019 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03854019 about?
NCT03854019 is a clinical study titled "Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease". The purpose of this study is to assess efficacy and safety of dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg) in patients with irritability due to Huntington's disease.
What is the current status of trial NCT03854019?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2019-08-05. Estimated completion is 2022-11-11.
What interventions are being tested in trial NCT03854019?
The interventions under investigation include: Placebo (DRUG), Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg) (DRUG).
Who is sponsoring clinical trial NCT03854019?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.